Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03701282
Title Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)

chronic lymphocytic leukemia/small lymphocytic lymphoma

chronic lymphocytic leukemia


Ibrutinib + Obinutuzumab

Ibrutinib + Obinutuzumab + Venetoclax

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.